Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease

Hypertension

Volumn 67, Issue 6, 2016, Pages 1205-1210

  Rimoldi, Stefano F ^a   Messerli, Franz H ^a   Cerny, David ^a   Gloekler, Steffen ^a   Traupe, Tobias ^a   Laurent, Stéphane ^b   Seiler, Christian ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

central blood pressure; coronary artery disease; heart rate; ivabradine; stroke volume; ventricular vascular mismatch

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NITRIC ACID DERIVATIVE; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART CATHETERIZATION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BENZAZEPINES; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84964319792     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07250     Document Type: Article

References (30)

1. Kjekshus JK, Importance of heart rate in determining beta-blocker efficacy in acute and long-Term acute myocardial infarction intervention trials. Am J Cardiol 1986 57 43F 49F
2. Prichard BN, Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-Adrenoceptor antagonists. Z Kardiol 1990 79 suppl 3 99 103
3. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, SIGNIFY Investigators Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014 371 1091 1099. doi: 10.1056/NEJMoa1406430
4. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008 372 807 816. doi: 10.1016/S0140-6736(08)61170-8
5. Beltrame JF, Ivabradine and the SIGNIFY conundrum. Eur Heart J 2015 36 3297 3299. doi: 10.1093/eurheartj/ehv368
6. Ferrari R, Fox KM, The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J 2015 36 2042 2046. doi: 10.1093/eurheartj/ehv150
7. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010 376 875 885. doi: 10.1016/S0140-6736(10)61198-1
8. McMurray JJ, It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J 2015 36 2047 2049. doi: 10.1093/eurheartj/ehv190
9. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB, Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009 54 409 413. doi: 10.1161/HYPERTENSIONAHA.109.133801
10. Pucci G, Ranalli MG, Battista F, Schillaci G, Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension. Hypertension 2016 67 316 324. doi: 10.1161/HYPERTENSIONAHA.115.06467
11. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB, Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006 19 214 219. doi: 10.1016/j.amjhyper.2005.08.007
12. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB, A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008 26 351 356. doi: 10.1097/HJH.0b013e3282f283c9
13. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A, Vogel R, Seiler C, The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014 100 160 166. doi: 10.1136/heartjnl-2013-304880
14. Mahieu D, Kips J, Rietzschel ER, De Buyzere ML, Verbeke F, Gillebert TC, De Backer GG, De Bacquer D, Verdonck P, Van Bortel LM, Segers P, Asklepios investigators Noninvasive assessment of central and peripheral arterial pressure (waveforms): implications of calibration methods. J Hypertens 2010 28 300 305. doi: 10.1097/HJH.0b013e3283340a1a
15. Gardner RM, Direct blood pressure measurement-dynamic response requirements. Anesthesiology 1981 54 227 236
16. Izzo JL Jr, Khan SU, Saleem O, Osmond PJ, Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. J Am Soc Hypertens 2015 9 526 535. doi: 10.1016/j.jash.2015.03.009
17. Safar ME, Protogerou AD, Blacher J, Statins, central blood pressure, and blood pressure amplification. Circulation 2009 119 9 12. doi: 10.1161/CIRCULATIONAHA.108.824532
18. Haesler E, Lyon X, Pruvot E, Kappenberger L, Hayoz D, Confounding effects of heart rate on pulse wave velocity in paced patients with a low degree of atherosclerosis. J Hypertens 2004 22 1317 1322
19. Lantelme P, Mestre C, Lievre M, Gressard A, Milon H, Heart rate: an important confounder of pulse wave velocity assessment. Hypertension 2002 39 1083 1087
20. Boutouyrie P, Beaussier H, Achouba A, Laurent S, EXPLOR trialists Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hypertens 2014 32 108 114. doi: 10.1097/HJH.0000000000000014
21. Albaladejo P, Challande P, Kakou A, Benetos A, Labat C, Louis H, Safar ME, Lacolley P, Selective reduction of heart rate by ivabradine: effect on the visco-elastic arterial properties in rats. J Hypertens 2004 22 1739 1745
22. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 113 1213 1225. doi: 10.1161/CIRCULATIONAHA.105.595496
23. Williams B, Lacy PS, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol 2009 54 705 713. doi: 10.1016/j.jacc.2009.02.088
24. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366 895 906. doi: 10.1016/S0140-6736(05)67185-1
25. Dillinger JG, Maher V, Vitale C, Henry P, Logeart D, Manzo Silberman S, Allée G, Levy BI, Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. Hypertension 2015 66 1138 1144. doi: 10.1161/HYPERTENSIONAHA.115.06091
26. Bangalore S, Sawhney S, Messerli FH, Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008 52 1482 1489. doi: 10.1016/j.jacc.2008.06.048
27. Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLOR Trialist Group Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-Atenolol combination: the EXPLOR study. Hypertension 2010 55 1314 1322. doi: 10.1161/HYPERTENSIONAHA.109.148999
28. Laurent P, Marenco P, Castagna O, Smulyan H, Blacher J, Safar ME, Differences in central systolic blood pressure and aortic stiffness between aerobically trained and sedentary individuals. J Am Soc Hypertens 2011 5 85 93. doi: 10.1016/j.jash.2011.01.003
29. Montalescot G, Sechtem U, Achenbach S, 2013 ESC Guidelines on the management of stable coronary artery disease. Eur Heart J 2013 34 2949 3003
30. Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M, Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013 62 1977 1985. doi: 10.1016/j.jacc.2013.07.027